Organon & Co. (OGN)

↓ Download CSV

CIK 0001821825 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

In fiscal 2025, Organon & Co. reported revenue of $6.22B, down 2.9% from the prior year. The company was profitable, with a net margin of 3.0% and a gross margin of 53.3%. It held $12.87B in total assets against $12.12B in total liabilities.

Key ratios (FY2025)

53.3%
Gross margin
3.0%
Net margin
24.9%
Return on equity
-2.9%
Revenue growth (YoY)
Metric (FY)20252024202320222021202020192018
Revenue$6.22B$6.40B$6.26B$6.17B$6.30B$6.53B$7.78B
Cost of Revenue$2.90B$2.69B$2.52B$2.29B$2.38B$2.12B$2.27B
Gross Profit$3.31B$3.71B$3.75B$3.88B
Net Income$187.00M$864.00M$1.02B$917.00M$1.35B$2.16B$3.22B
EPS (Diluted)$0.72$3.33$3.99$3.59$5.31$8.52$12.69
Total Assets$12.87B$13.10B$12.06B$10.96B$10.68B$10.11B
Total Liabilities$12.12B$12.63B$12.13B$11.85B
Shareholders' Equity$752.00M$472.00M-$70.00M-$892.00M-$1.51B$5.49B$7.04B$6.35B
Cash & Equivalents$574.00M$675.00M$693.00M$706.00M$737.00M$12.00M
Operating Cash Flow$700.00M$939.00M$799.00M$858.00M
Capital Expenditures$162.00M$175.00M$251.00M$196.00M$192.00M$255.00M$92.00M
Shares Outstanding260.76M259.15M256.27M255.17M254.19M253.52M253.52M
Dividends Per Share$0.34$1.12$1.12$1.12$0.56